Life Technologies and RainTree collaborate, 9/13
September 2013—Life Technologies and RainTree Oncology Services have entered into a collaborative agreement designed to further the advancement of personalized care for cancer patients.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Seegene and Eidia join forces to bring multiplex molecular diagnostic tests to Japan, 9/13
Seegene has entered into a collaborative agreement with Eidia, the in vitro diagnostics subsidiary arm of Eisai Co., headquartered in Japan. Through this agreement, Eidia gains access to Seegene’s portfolio of Toce technology-based multiplex molecular diagnostic tests for the Japanese diagnostic test market.
WASPLab system installation, 9/13
The CHU de Québec, a health care institution in Québec, and Copan Diagnostics announced the full installation of the WASPLab laboratory automation and digital microbiology system in Hôpital de l’Enfant-Jésus, one of the five hospitals forming the CHU de Québec.
Horizon and Riken sign distribution deal, 9/13
Horizon Diagnostics has signed a distribution agreement with Riken Genesis under which Riken will become the sole distributor of HDx’s molecular reference standards in Japan. Riken Genesis offers genomic products and services to a range of research institutions and corporations and is a CAP-accredited laboratory for genome analysis services.
Anti-Toxoplasma performance panel, 9/13
SeraCare Life Sciences has introduced a new AccuSet anti-Toxoplasma performance panel.
Clinical study for GI panel, 9/13
BioFire Diagnostics has begun clinical and analytical studies at several hospital-based laboratories in the U.S. to evaluate the company’s FilmArray gastrointestinal panel. BioFire plans to seek CE IVD marking and FDA clearance for the test.
Slide-staining instruments, 9/13
ELITechGroup Biomedical Systems has launched a new Series 2 generation of Aerospray slide stainers. The stainers have large touchscreens, bar-code readers, and intuitive user interfaces with language selection and help screens.
Small-volume tube system, 9/13
The Eppendorf Tube 5.0 mL system, from Eppendorf North America, handles volumes up to 5 mL. The tubes feature a snap cap for single-hand operation and a compact conical design, removing the risk of contamination associated with manipulating small volumes in large tubes.
Beckman expands flow cytometry line, 9/13
Beckman Coulter Life Sciences has acquired the flow cytometry business assets of ReaMetrix India, a Bangalore-based life science technology company. The transaction provides Beckman Coulter with temperature-stable, single-dose, multi-color antibody cocktails targeting the HIV monitoring and clinical research markets.
Automated HbA1c testing system, 9/13
Mercy Medical Center in Canton, Ohio, has implemented advanced clinical laboratory diagnostic technology for conducting on-demand HbA1c diabetes testing, as well as analysis of red blood cell, white blood cell, and platelet counts. Mercy did this by installing Sysmex America’s XN-9000 Lavender Top Management configuration. As North America’s first installation of its kind, the Sysmex Lavender Top Management system, designed and manufactured by Bio-Rad Laboratories and Sysmex America, builds on Mercy’s Sysmex XN-9000 system and further optimizes lab workflow, staffing,